Abstracts

EXPECTATIONS OF PREVENTIVE BENEFITS & HIV-RELATED RISK BEHAVIORS IN HPTN069/ACTG5305

When clinical trial participants hold a preventive misconception (PM), i.e., expectations that experimental interventions will confer protection from HIV infection, they may engage in behaviors possibly increasing their risk of acquiring HIV. We evaluated these issues in HPTN069/ACTG A5305 [NCT01505114], a double-blind, phase 2 study that compared 4 potential preexposure prophylaxis (PrEP) regimens: maraviroc (MVC);…

LONG-ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV

The efficacy of daily oral pre-exposure prophylaxis (PrEP) to prevent HIV-1 infection is highly dependent on adherence. Lenacapavir (LEN) is a potent first-in-class HIV capsid (CA) inhibitor with long-acting pharmacokinetics (PK), making it attractive for PrEP. We previously derived a simian-tropic HIV-1 infectious molecular clone (stHIV-A19) that encodes HIV-1 CA and replicates to high titers…

SARS-CoV-2 VACCINE EFFECTIVENESS FOR IN-HOSPITAL MORTALITY – ZAMBIA, 2021

Multiple vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have demonstrated high effectiveness for reducing severe COVID-19 and mortality. However, vaccine effectiveness data from the African region, where COVID-19 epidemiology and SARS-CoV-2 vaccine coverage differs from other regions, are limited. This study aimed to assess vaccine effectiveness in preventing in-hospital COVID-19 mortality in Zambia.…

STOPCoV: SAFETY AND EFFICACY OF PREVENTATIVE COVID VACCINES

In attempts to rapidly immunize a greater proportion of the Ontario population against COVID, public health officials recommended extending the interval between vaccine doses and allowed ‘mixing of vaccine types’. The impact of these decisions on the antibody response to the vaccine, particularly in the community dwelling elderly population is unknown. The STOPCoV study is…

EXTENDED-RELEASE NALTREXONE LOWERS INJECTION USE IN JUSTICE-INVOLVED PERSONS WITH HIV

Opioid use disorder (OUD) and injection drug use (IDU) behavior are both highly prevalent among justice involved individuals, with the latter increasing risk for HIV acquisition. Medications for opioid use disorder (MOUD), including extended-release naltrexone (XR-NTX), are associated with increased retention on antiretroviral therapy (ART) and viral suppression in persons with HIV (PWH). However, the…